• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19.

作者信息

Targher G, Mantovani A, Byrne C D, Wang X-B, Yan H-D, Sun Q-F, Pan K-H, Zheng K I, Chen Y-P, Eslam M, George J, Zheng M-H

机构信息

Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale Stefani 1, 37126 Verona, Italy.

Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale Stefani 1, 37126 Verona, Italy.

出版信息

Diabetes Metab. 2020 Nov;46(6):505-507. doi: 10.1016/j.diabet.2020.06.001. Epub 2020 Jun 4.

DOI:10.1016/j.diabet.2020.06.001
PMID:
32505652
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7270805/
Abstract
摘要

相似文献

1
Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19.代谢功能障碍相关脂肪性肝病及中性粒细胞与淋巴细胞比值升高对新型冠状病毒肺炎严重程度的有害影响。
Diabetes Metab. 2020 Nov;46(6):505-507. doi: 10.1016/j.diabet.2020.06.001. Epub 2020 Jun 4.
2
Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight.2019冠状病毒病在肥胖人群中的严重程度：代谢功能障碍相关脂肪性肝病成为焦点。
World J Gastroenterol. 2021 Apr 28;27(16):1738-1750. doi: 10.3748/wjg.v27.i16.1738.
3
Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis.非酒精性脂肪性肝病和代谢相关脂肪性肝病与 COVID-19 相关重症监护病房结局的关联：系统评价和荟萃分析。
Medicina (Kaunas). 2023 Jul 3;59(7):1239. doi: 10.3390/medicina59071239.
4
Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.代谢功能障碍相关脂肪性肝病与 2019 年冠状病毒病：临床关系和当前管理。
Lipids Health Dis. 2021 Oct 3;20(1):126. doi: 10.1186/s12944-021-01564-z.
5
Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019.代谢相关脂肪性肝病和非酒精性脂肪性肝病与 2019 冠状病毒病住院患者死亡和插管的晚期纤维化的相互作用。
Hepatol Commun. 2022 Aug;6(8):2000-2010. doi: 10.1002/hep4.1957. Epub 2022 Apr 19.
6
Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019.血清白细胞介素-6 水平与 2019 年严重冠状病毒病患者代谢功能障碍相关脂肪性肝病的相关性和相互作用。
Front Endocrinol (Lausanne). 2021 Mar 8;12:604100. doi: 10.3389/fendo.2021.604100. eCollection 2021.
7
Implications of metabolic dysfunction associated fatty liver disease in COVID-19.代谢功能障碍相关脂肪性肝病在2019冠状病毒病中的意义
World J Clin Cases. 2023 Feb 26;11(6):1275-1286. doi: 10.12998/wjcc.v11.i6.1275.
8
Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis.代谢相关脂肪性肝病增加 COVID-19 的严重程度：一项荟萃分析。
Dig Liver Dis. 2021 Feb;53(2):153-157. doi: 10.1016/j.dld.2020.09.007. Epub 2020 Sep 17.
9
Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.代谢相关脂肪性肝病与重症 COVID-19 风险增加相关：一项系统评价与荟萃分析
Front Med (Lausanne). 2021 Mar 12;8:626425. doi: 10.3389/fmed.2021.626425. eCollection 2021.
10
Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.慢性肾脏病发生时代谢功能障碍相关脂肪/脂肪变性肝病的严重程度和缓解情况。
J Am Heart Assoc. 2024 Mar 5;13(5):e032604. doi: 10.1161/JAHA.123.032604. Epub 2024 Feb 23.

引用本文的文献

1
Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis.非酒精性脂肪肝和代谢相关脂肪性肝病与 COVID-19 结局的关系：系统评价和荟萃分析。
World J Gastroenterol. 2023 Jun 7;29(21):3362-3378. doi: 10.3748/wjg.v29.i21.3362.
2
Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update.新冠病毒病合并非酒精性脂肪性肝病患者的肝损伤：最新进展
Arch Med Sci Atheroscler Dis. 2023 Feb 23;8:e1-e10. doi: 10.5114/amsad/160950. eCollection 2023.
3
Mortality in patients with Coronavirus disease 2019 (COVID- 19) and its clinicoradiological and laboratory correlates: A retrospective study.

本文引用的文献

1
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.代谢功能障碍相关脂肪性肝病且纤维化评分升高的患者感染新型冠状病毒肺炎后出现重症的风险。
Gut. 2020 Aug;69(8):1545-1547. doi: 10.1136/gutjnl-2020-321611. Epub 2020 May 15.
2
Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19.中性粒细胞与淋巴细胞比值可作为 COVID-19 住院患者死亡的独立危险因素。
J Infect. 2020 Jul;81(1):e6-e12. doi: 10.1016/j.jinf.2020.04.002. Epub 2020 Apr 10.
3
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
2019年冠状病毒病（COVID-19）患者的死亡率及其临床影像学和实验室相关因素：一项回顾性研究。
J Family Med Prim Care. 2022 Oct;11(10):6197-6203. doi: 10.4103/jfmpc.jfmpc_364_22. Epub 2022 Oct 31.
4
SARS-CoV-2-mediated liver injury: pathophysiology and mechanisms of disease.SARS-CoV-2 介导的肝损伤：发病机制和疾病的发生机制。
Inflamm Res. 2023 Feb;72(2):301-312. doi: 10.1007/s00011-022-01683-y. Epub 2022 Dec 20.
5
Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective.2019冠状病毒病感染的肝脏表现：临床与实验室视角
World J Virol. 2022 Nov 25;11(6):453-466. doi: 10.5501/wjv.v11.i6.453.
6
Investigation of comorbidities of COVID-19 patients with hepatosteatosis using latent class analysis.采用潜在类别分析方法调查 COVID-19 合并脂肪性肝病患者的共病情况。
Front Public Health. 2022 Sep 29;10:990848. doi: 10.3389/fpubh.2022.990848. eCollection 2022.
7
The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis.代谢相关脂肪性肝病与新型冠状病毒肺炎临床结局的关联：一项系统评价和Meta分析
Kans J Med. 2022 Jul 21;15(2):241-246. doi: 10.17161/kjm.vol15.16522. eCollection 2022.
8
COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD.COVID-19 大流行：对 SARS-CoV-2 感染与 MAFLD 之间相互作用的深入了解。
Int J Biol Sci. 2022 Jul 11;18(12):4756-4767. doi: 10.7150/ijbs.72461. eCollection 2022.
9
Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.特殊人群 COVID-19 疫苗接种的获益-风险评估。
Vaccine. 2022 Jul 30;40(32):4348-4360. doi: 10.1016/j.vaccine.2022.05.067. Epub 2022 May 27.
10
Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol.新冠病毒肺炎住院后房颤患者使用达比加群：ANIBAL方案的更新
Drugs Context. 2022 Jan 24;11. doi: 10.7573/dic.2021-9-4. eCollection 2022.
代谢相关脂肪性肝病新定义：国际专家共识声明。
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
4
Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.2019年冠状病毒病（COVID-19）重症患者的中性粒细胞与淋巴细胞比值及淋巴细胞与C反应蛋白比值：一项荟萃分析。
J Med Virol. 2020 Oct;92(10):1733-1734. doi: 10.1002/jmv.25819. Epub 2020 Apr 8.
5
The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: a systematic review.中性粒细胞与淋巴细胞比值在评估肝纤维化和肝硬化中的作用：系统评价。
Expert Rev Gastroenterol Hepatol. 2018 May;12(5):503-513. doi: 10.1080/17474124.2018.1463158. Epub 2018 Apr 16.
6
Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease.中性粒细胞与淋巴细胞比值：预测非酒精性脂肪性肝病患者脂肪性肝炎和纤维化的新标志物。
Liver Int. 2012 Feb;32(2):297-302. doi: 10.1111/j.1478-3231.2011.02639.x. Epub 2011 Sep 8.